<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24244774</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine.</ArticleTitle><Pagination><StartPage>e2538</StartPage><MedlinePgn>e2538</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2538</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0002538</ELocationID><Abstract><AbstractText>Human enterovirus 71 (EV71) is a significant cause of morbidity and mortality from Hand, Foot and Mouth Disease (HFMD) and neurological complications, particularly in young children in the Asia-Pacific region. There are no vaccines or antiviral therapies currently available for prevention or treatment of HFMD caused by EV71. Therefore, the development of therapeutic and preventive strategies against HFMD is of growing importance. We report the immunogenic and safety profile of inactivated, purified EV71 preparations formulated with aluminum hydroxide adjuvant in preclinical studies in mice and rabbits. In mice, the candidate vaccine formulations elicited high neutralizing antibody responses. A toxicology study of the vaccine formulations planned for human use performed in rabbits showed no vaccine-related pathological changes and all animals remained healthy. Based on these preclinical studies, Phase 1 clinical testing of the EV71 inactivated vaccine was initiated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hwa</LastName><ForeName>Shi-Hsia</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Inviragen (Singapore) Pte. Ltd., Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yock Ann</ForeName><Initials>YA</Initials></Author><Author ValidYN="Y"><LastName>Brewoo</LastName><ForeName>Joseph N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Partidos</LastName><ForeName>Charalambos D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Osorio</LastName><ForeName>Jorge E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Santangelo</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Authors SHH, YAL, JNB, CDP, JEO, and JDS are employees of Inviragen. This does not alter our adherence to all PLOS policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24244774</ArticleId><ArticleId IdType="pmc">PMC3820736</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0002538</ArticleId><ArticleId IdType="pii">PNTD-D-13-00153</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, et al. (1999) Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341: 936&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Huang YC, Lin TY (1998) Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 352: 367&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9717926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Mohan A, Podin Y, Perera D, et al. (2009) Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis 9: 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637878</ArticleId><ArticleId IdType="pubmed">19152683</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10 11 778&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>(2012) WPRO Hand, Foot, and Mouth Disease Situation Update, 15 May 2012. Western Pacific Regional Office of the World Health Organization. pp. 4.</Citation></Reference><Reference><Citation>(2012) Updates on HFMD Situation in Singapore (23 May 2012). Hand, Foot &amp; Mouth Disease: Updates: Singapore Ministry of Health.</Citation></Reference><Reference><Citation>Pallansch MA, Roos R (2007) Enteroviruses: polioviruses, coxsackieviruses, and newer enteroviruses. In: Knipe DM, Howley PM, Griffin DE, editors. Fields Virology. Philadelphia, PA Lippincott Williams &amp; Wilkins. pp. 839&#x2013;894.</Citation></Reference><Reference><Citation>Nagata N, Shimizu H, Ami Y, Tano Y, Harashima A, et al. (2002) Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 67: 207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11992581</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15: 798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, et al. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15: 794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS, Maher K, Kilpatrick DR, Flemister MR, Brown BA, et al. (1999) Typing of human enteroviruses by partial sequencing of VP1. J Clin Microbiol 37: 1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84754</ArticleId><ArticleId IdType="pubmed">10203472</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, et al. (2012) Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 6: e1737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429393</ArticleId><ArticleId IdType="pubmed">22953003</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73: 9969&#x2013;9975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam IC, Abubakar S (2009) Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 10 3 404&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoke-Fun C, AbuBakar S (2006) Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC Microbiol 6: 74.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, et al. (1999) Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 29: 184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT (2010) Formaldehyde-inactivated whole virus vaccine protects a murine model of Enterovirus 71 encephalomyelitis against disease. J Virol 84: 661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, et al. (2012) Production of EV71 vaccine candidates. Hum Vaccin Immunother 8: 1775&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST (2006) Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24: 2944&#x2013;2951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J (2011) Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS ONE 6: e21757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al. (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: 7444&#x2013;7451.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8: 1671&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386&#x2013;9395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Dong C, Li X, Gao Q, Guo Z, et al. (2012) Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS ONE 7: e46043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460965</ArticleId><ArticleId IdType="pubmed">23029378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, et al. (2012) Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates. Clin Dev Immunol 2012: 831282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="pubmed">23008736</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30: 3295&#x2013;3303.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, et al. (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381: 2024&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, et al. (2013) A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31: 2471&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahnemann HG (1990) Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 8: 299&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7173316</ArticleId><ArticleId IdType="pubmed">2204242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, et al. (2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6: e20005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, et al. (2013) The Enterovirus 71 A-particle Forms a Gateway to Allow Genome Release: A CryoEM Study of Picornavirus Uncoating. PLoS Pathog 9: e1003240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S, Chow M, Hogle JM (1996) The poliovirus 135S particle is infectious. J Virol 70: 7125&#x2013;7131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190765</ArticleId><ArticleId IdType="pubmed">8794359</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdier F (2002) Non-clinical vaccine safety assessment. Toxicology 174: 37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11972990</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, et al. (2005) Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23: 1359&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661384</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, et al. (2004) A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78: 7916&#x2013;7924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Duo J, Liu J, Ma C, Zhang L, et al. (2011) A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect 13: 862&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">21612764</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Wang YF, Yu CK, Su IJ, Wang JR (2012) Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 422: 132&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">22078110</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, et al. (2011) A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86 4 2121&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Partidos CD, Santangelo JD, Osorio JE (2013) Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS ONE 8: e59501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3602422</ArticleId><ArticleId IdType="pubmed">23527208</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ML, Chiang PS, Chia MY, Luo ST, Chang LY, et al. (2013) Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development. PLoS Negl Trop Dis 7: e2067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3573098</ArticleId><ArticleId IdType="pubmed">23459633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li C, He D, Cheng T, Ge S, et al. (2013) Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine 31: 425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">23088887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung SH, Wang SF, Huang CW, Hsu CC, Liu HF, et al. (2007) Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998&#x2013;2005. Clin Microbiol Infect 13: 782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">17488328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, et al. (2009) Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27: 3153&#x2013;3158.</Citation><ArticleIdList><ArticleId IdType="pubmed">19446185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BY, Wateska AR, Bailey RR, Tai JH, Bacon KM, et al. (2010) Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine 28: 7731&#x2013;7736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989421</ArticleId><ArticleId IdType="pubmed">20923711</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>